I'll research PFG (Principal Financial Group) before writing the preview. Let me gather recent filings, earnings, news, and price data.Let me read the most recent earnings call, the Q1 release, and the recent AUM 8-K.Let me get consensus estimates and recent analyst commentary via web search, and pull the Q1 earnings release figures.Let me quickly confirm PFG's 2026 full-year targets from the Q4 outlook call.# Principal Financial Group (PFG) — Q2 2026 Earnings Preview
Report timing: After market close, Monday, July 27, 2026 | Conference call 10:00 a.m. ET, July 28 Recent price: ~$109 (as of 7/24) | YTD: ~+22% (from $89.42 on 1/2 to $109.43 on 7/24)
PFG heads into this print near the top of its 52-week range after a powerful run — shares climbed from ~$89 in January to a peak of ~$114 in mid-July, then pulled back roughly 6% over the following week (to $107.32 on 7/23) before stabilizing near $109. The stock has meaningfully outpaced life-insurance peers such as MET and PRU year-to-date, so expectations are elevated and there is less margin for error on a "just in-line" quarter.
Consensus: Street looks for roughly $2.32 in operating EPS (range ~$2.31–$2.34), representing ~7–8% growth versus $2.16 in Q2 2025. Note PFG has a mixed-to-positive surprise history and beat handily in Q1 (see below).
Q1 was a strong start and sets a high internal benchmark: - Operating EPS of $2.17 (ex-significant variances), +13% YoY — above the high end of the 9–12% target range - ROE 16.1% (midpoint of the raised 15–17% target); enterprise margin ~30%, +190 bps YoY - $374M returned to shareholders ($200M buybacks + $174M dividends); dividend raised for a 12th straight quarter to $0.82 (+8% YoY) - Excess & available capital of ~$1.4B; RBC ratio ~400% (vs. 375% target)
The standout was Benefits & Protection, where pretax operating earnings jumped 41% YoY on favorable Specialty Benefits underwriting (loss ratio 58.5%) and strong Life mortality.
PFG's July 20 pre-earnings 8-K disclosed total managed AUM of $808.0 billion as of 6/30/26 — up sharply from $770B at Q1-end — split $601.9B in Investment Management and $168.5B in International Pension. Management flagged an approximate +6.4% positive impact from markets, FX and other items during the quarter. Rising equity markets and FX tailwinds should lift fee-based revenue across RIS, Investment Management and International Pension. The key question is whether net flows keep pace with the market lift.
This is the most important swing factor. Management repeatedly noted Q1 had no real estate transaction activity (real estate is ~50% of the alts book), which depressed VII, but they expect a pickup in Q2–Q4 and full-year 2026 VII to improve vs. 2025. Watch for: (a) whether real estate monetizations materialized in Q2, and (b) the below-the-line real estate depreciation reclassification introduced in Q1 (a presentation change with no impact on adjusted results). Any VII shortfall would show up as a "significant variance."
Specialty Benefits has been the earnings engine. Management guided the full-year loss ratio to the low end or slightly below the 60–64% range, but explicitly warned that Q2 is seasonally the highest quarter for dental claims, so the SBD loss ratio should tick up sequentially from Q1's exceptional 58.5%. Don't mistake normal seasonal loss-ratio drift for deterioration. Also watch premium/fee growth building toward the 5–9% target (weighted to 2H) and any early contribution from the small Alabama dental network acquisition.
Q1 Life earnings ($37M, +$23M YoY) were unusually strong on favorable mortality (roughly 50/50 incidence and severity). Management cautioned this reflected "positive volatility" and guided full-year margin toward the low end of the 12–16% range — so a sequential give-back is expected and would be consistent with guidance.
Q1 delivered a very strong $1.8B of account-value net cash flow, boosted by large-case transfer deposit wins and $12B of total transfer deposits (+35%). Management guided that Q1 is seasonally the strongest and that remaining quarters face higher withdrawal dollars (from strong markets) plus large-case lumpiness. PRT pipeline was also flagged as light in Q2 (following a huge Q4 2025 industry quarter). Focus on RIS margin, which management expects at the upper end of the raised 38–41% range.
The recurring debate: record gross sales (Q1 +21% YoY) have been offset by elevated redemptions concentrated in U.S. active equity funds in the wealth channel. Management expects non-affiliated net cash flow to improve over the balance of the year as redemptions normalize, and highlighted a committed pipeline that has grown to ~$9B. Watch net flows, the fee-rate trajectory (mix shift toward private markets creates noise), and private-markets momentum.
Q1 IP earnings (~$80M) were flattered by a ~$7M China performance fee; management guided a cleaner run-rate in the mid-$70Ms, with FX finally turning to a tailwind. Also watch for updates on the runoff Chile annuity divestiture (~$30M pretax, ~$65M revenue), expected to close ~Q3 2026 and fund elevated 2026 buybacks.
2026 guidance is $1.5–1.8B of total deployment ($800M–$1.1B buybacks + a rising ~40%-payout dividend). With Q1 buybacks at $200M, watch the buyback cadence and whether excess capital (~$1.4B) plus the pending Chile proceeds support a step-up. A 13th consecutive dividend increase is plausible.
PFG enters Q2 with a confirmed AUM tailwind ($808B, +6.4% market/FX lift), momentum across its three strategic growth pillars (retirement ecosystem, SMB, global asset management), and management reiterating confidence in all 2026 targets (9–12% EPS growth, 15–17% ROE, 75–85% free-capital-flow conversion). The most likely sources of upside/downside relative to the ~$2.32 consensus are VII/real estate transaction timing, the Specialty Benefits loss ratio (seasonally higher dental), and whether Life mortality and RIS/IM net flows normalize as guided. With the stock near highs, watch the quality and sustainability of the beat, capital-return pace, and any commentary on labor-market health as much as the headline EPS.
Sources: PFG Q1 2026 and Q4 2025/2026-outlook earnings calls; July 20, 2026 AUM 8-K; consensus estimates via public analyst previews; market data via price history.